Abstract
Endothelial dysfunction is an important process in the development of atherosclerotic cardiovascular disease, while it is also a major pathophysiological mechanism underlying vasculogenic erectile dysfunction (ED). Expectedly, these two prevalent disorders are linked also at the clinical level: ED is common in patients with overt and silent coronary artery disease, while ED is increasingly being regarded as the early clinical manifestation of a generalized vascular disease and carries an independent risk for future cardiovascular events. The emerging awareness of ED as a barometer for cardiovascular disease offers a unique opportunity to enhance preventive vascular health in men. Lifestyle and risk factor modification, as well as pharmacologic therapy (both phosphodiesterase type-5 inhibitors and non-ED-targeting drugs), appear to confer additional benefit both in terms of ED treatment and overall cardiovascular risk; this benefit may be related, at least partly, to the improvement of endothelial function and anti-inflammatory effects. The present review identifies pathophysiologic links between endothelial dysfunction, ED and coronary artery disease, presents methodological aspects regarding penile and systemic endothelial function, and discusses the clinical implications in terms of diagnosis of ED, assessment of patient risk, and treatment.
Keywords: Endothelial dysfunction, erectile dysfunction, nitric oxide, coronary artery disease, phosphodiesterase type-5 inhibitors
Current Pharmaceutical Design
Title: The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Volume: 14 Issue: 35
Author(s): Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Dimitrios Terentes-Printzios and Christodoulos Stefanadis
Affiliation:
Keywords: Endothelial dysfunction, erectile dysfunction, nitric oxide, coronary artery disease, phosphodiesterase type-5 inhibitors
Abstract: Endothelial dysfunction is an important process in the development of atherosclerotic cardiovascular disease, while it is also a major pathophysiological mechanism underlying vasculogenic erectile dysfunction (ED). Expectedly, these two prevalent disorders are linked also at the clinical level: ED is common in patients with overt and silent coronary artery disease, while ED is increasingly being regarded as the early clinical manifestation of a generalized vascular disease and carries an independent risk for future cardiovascular events. The emerging awareness of ED as a barometer for cardiovascular disease offers a unique opportunity to enhance preventive vascular health in men. Lifestyle and risk factor modification, as well as pharmacologic therapy (both phosphodiesterase type-5 inhibitors and non-ED-targeting drugs), appear to confer additional benefit both in terms of ED treatment and overall cardiovascular risk; this benefit may be related, at least partly, to the improvement of endothelial function and anti-inflammatory effects. The present review identifies pathophysiologic links between endothelial dysfunction, ED and coronary artery disease, presents methodological aspects regarding penile and systemic endothelial function, and discusses the clinical implications in terms of diagnosis of ED, assessment of patient risk, and treatment.
Export Options
About this article
Cite this article as:
Vlachopoulos Charalambos, Ioakeimidis Nikolaos, Terentes-Printzios Dimitrios and Stefanadis Christodoulos, The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease, Current Pharmaceutical Design 2008; 14 (35) . https://dx.doi.org/10.2174/138161208786898716
DOI https://dx.doi.org/10.2174/138161208786898716 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Platelets and HIV-1 Infection: Old and New Aspects
Current HIV Research Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry The Postprandial State and its Influence on the Development of Atherosclerosis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adipocytokines; Cause for Metabolic Syndrome
Current Medicinal Chemistry - Central Nervous System Agents Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Targeted Metabolomics Reveals Hippurate as a Urinary Potential Marker for Diabetic Nephropathy
Current Metabolomics Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets The Role of EC-IC Bypass in Critical Cerebral Hemodynamics of Different Origin
Current Hypertension Reviews Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design The Immune System and the Brain: Crosstalk with a Broad Impact From Host Defense to Cognition
Current Neurovascular Research MicroRNA Biogenesis in Hypoxia
MicroRNA Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design